COVID-19 in lung transplant recipients: A case series from Milan, Italy.
Identifieur interne : 001470 ( Main/Corpus ); précédent : 001469; suivant : 001471COVID-19 in lung transplant recipients: A case series from Milan, Italy.
Auteurs : Letizia Corinna Morlacchi ; Valeria Rossetti ; Lorenzo Gigli ; Francesco Amati ; Lorenzo Rosso ; Stefano Aliberti ; Mario Nosotti ; Francesco BlasiSource :
- Transplant infectious disease : an official journal of the Transplantation Society [ 1399-3062 ] ; 2020.
English descriptors
- KwdEn :
- Aged (MeSH), Anti-Bacterial Agents (therapeutic use), Anticoagulants (therapeutic use), Blood Gas Analysis (MeSH), COVID-19 (drug therapy), COVID-19 (immunology), Cystic Fibrosis (surgery), Deprescriptions (MeSH), Enzyme Inhibitors (therapeutic use), Female (MeSH), Graft Rejection (prevention & control), Heparin, Low-Molecular-Weight (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Idiopathic Pulmonary Fibrosis (surgery), Immunosuppressive Agents (therapeutic use), Italy (MeSH), Lung Diseases, Interstitial (surgery), Lung Transplantation (MeSH), Male (MeSH), Middle Aged (MeSH), Pulmonary Emphysema (surgery), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Anticoagulants, Enzyme Inhibitors, Heparin, Low-Molecular-Weight, Hydroxychloroquine, Immunosuppressive Agents.
- geographic : Italy.
- drug therapy : COVID-19.
- immunology : COVID-19.
- prevention & control : Graft Rejection.
- surgery : Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial, Pulmonary Emphysema.
- Aged, Blood Gas Analysis, Deprescriptions, Female, Humans, Lung Transplantation, Male, Middle Aged, SARS-CoV-2, Treatment Outcome.
Abstract
Limited data are currently available regarding the course of COVID-19 in lung and solid organ transplant recipients. We hereby present four cases of SARS-CoV-2 pneumonia in lung transplant recipients from our center, set in Milan, Italy. We reduced immunosuppressive regimen in all these patients, typically holding the antiproliferative agent and augmenting steroids; everybody received hydroxychloroquine, initial empiric antibiotic treatment with piperacillin/tazobactam, and high-dose low molecular weight heparin. Clinical course seemed favorable in three of our patients, but one of them deteriorated after 10 days of hospitalization, probably due to an acute form of graft dysfunction triggered both by COVID-19 and a nosocomial bacterial infection, and eventually died. Although short-term prognosis could be considered benign in the majority of our patients, we should carefully monitor these individuals in order to detect early sign of clinical deterioration and graft dysfunction in the next few months.
DOI: 10.1111/tid.13356
PubMed: 32510771
Links to Exploration step
pubmed:32510771Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 in lung transplant recipients: A case series from Milan, Italy.</title><author><name sortKey="Morlacchi, Letizia Corinna" sort="Morlacchi, Letizia Corinna" uniqKey="Morlacchi L" first="Letizia Corinna" last="Morlacchi">Letizia Corinna Morlacchi</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Rossetti, Valeria" sort="Rossetti, Valeria" uniqKey="Rossetti V" first="Valeria" last="Rossetti">Valeria Rossetti</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Gigli, Lorenzo" sort="Gigli, Lorenzo" uniqKey="Gigli L" first="Lorenzo" last="Gigli">Lorenzo Gigli</name><affiliation><nlm:affiliation>Cardiovascular Disease Unit, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Amati, Francesco" sort="Amati, Francesco" uniqKey="Amati F" first="Francesco" last="Amati">Francesco Amati</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Rosso, Lorenzo" sort="Rosso, Lorenzo" uniqKey="Rosso L" first="Lorenzo" last="Rosso">Lorenzo Rosso</name><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Aliberti, Stefano" sort="Aliberti, Stefano" uniqKey="Aliberti S" first="Stefano" last="Aliberti">Stefano Aliberti</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Nosotti, Mario" sort="Nosotti, Mario" uniqKey="Nosotti M" first="Mario" last="Nosotti">Mario Nosotti</name><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Blasi, Francesco" sort="Blasi, Francesco" uniqKey="Blasi F" first="Francesco" last="Blasi">Francesco Blasi</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32510771</idno><idno type="pmid">32510771</idno><idno type="doi">10.1111/tid.13356</idno><idno type="wicri:Area/Main/Corpus">001470</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001470</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 in lung transplant recipients: A case series from Milan, Italy.</title><author><name sortKey="Morlacchi, Letizia Corinna" sort="Morlacchi, Letizia Corinna" uniqKey="Morlacchi L" first="Letizia Corinna" last="Morlacchi">Letizia Corinna Morlacchi</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Rossetti, Valeria" sort="Rossetti, Valeria" uniqKey="Rossetti V" first="Valeria" last="Rossetti">Valeria Rossetti</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Gigli, Lorenzo" sort="Gigli, Lorenzo" uniqKey="Gigli L" first="Lorenzo" last="Gigli">Lorenzo Gigli</name><affiliation><nlm:affiliation>Cardiovascular Disease Unit, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Amati, Francesco" sort="Amati, Francesco" uniqKey="Amati F" first="Francesco" last="Amati">Francesco Amati</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Rosso, Lorenzo" sort="Rosso, Lorenzo" uniqKey="Rosso L" first="Lorenzo" last="Rosso">Lorenzo Rosso</name><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Aliberti, Stefano" sort="Aliberti, Stefano" uniqKey="Aliberti S" first="Stefano" last="Aliberti">Stefano Aliberti</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Nosotti, Mario" sort="Nosotti, Mario" uniqKey="Nosotti M" first="Mario" last="Nosotti">Mario Nosotti</name><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Blasi, Francesco" sort="Blasi, Francesco" uniqKey="Blasi F" first="Francesco" last="Blasi">Francesco Blasi</name><affiliation><nlm:affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Transplant infectious disease : an official journal of the Transplantation Society</title><idno type="eISSN">1399-3062</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Anticoagulants (therapeutic use)</term><term>Blood Gas Analysis (MeSH)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (immunology)</term><term>Cystic Fibrosis (surgery)</term><term>Deprescriptions (MeSH)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Female (MeSH)</term><term>Graft Rejection (prevention & control)</term><term>Heparin, Low-Molecular-Weight (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Idiopathic Pulmonary Fibrosis (surgery)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Italy (MeSH)</term><term>Lung Diseases, Interstitial (surgery)</term><term>Lung Transplantation (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pulmonary Emphysema (surgery)</term><term>SARS-CoV-2 (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Anticoagulants</term><term>Enzyme Inhibitors</term><term>Heparin, Low-Molecular-Weight</term><term>Hydroxychloroquine</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Italy</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Graft Rejection</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Cystic Fibrosis</term><term>Idiopathic Pulmonary Fibrosis</term><term>Lung Diseases, Interstitial</term><term>Pulmonary Emphysema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Blood Gas Analysis</term><term>Deprescriptions</term><term>Female</term><term>Humans</term><term>Lung Transplantation</term><term>Male</term><term>Middle Aged</term><term>SARS-CoV-2</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Limited data are currently available regarding the course of COVID-19 in lung and solid organ transplant recipients. We hereby present four cases of SARS-CoV-2 pneumonia in lung transplant recipients from our center, set in Milan, Italy. We reduced immunosuppressive regimen in all these patients, typically holding the antiproliferative agent and augmenting steroids; everybody received hydroxychloroquine, initial empiric antibiotic treatment with piperacillin/tazobactam, and high-dose low molecular weight heparin. Clinical course seemed favorable in three of our patients, but one of them deteriorated after 10 days of hospitalization, probably due to an acute form of graft dysfunction triggered both by COVID-19 and a nosocomial bacterial infection, and eventually died. Although short-term prognosis could be considered benign in the majority of our patients, we should carefully monitor these individuals in order to detect early sign of clinical deterioration and graft dysfunction in the next few months.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32510771</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-3062</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Transplant infectious disease : an official journal of the Transplantation Society</Title><ISOAbbreviation>Transpl Infect Dis</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in lung transplant recipients: A case series from Milan, Italy.</ArticleTitle><Pagination><MedlinePgn>e13356</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/tid.13356</ELocationID><Abstract><AbstractText>Limited data are currently available regarding the course of COVID-19 in lung and solid organ transplant recipients. We hereby present four cases of SARS-CoV-2 pneumonia in lung transplant recipients from our center, set in Milan, Italy. We reduced immunosuppressive regimen in all these patients, typically holding the antiproliferative agent and augmenting steroids; everybody received hydroxychloroquine, initial empiric antibiotic treatment with piperacillin/tazobactam, and high-dose low molecular weight heparin. Clinical course seemed favorable in three of our patients, but one of them deteriorated after 10 days of hospitalization, probably due to an acute form of graft dysfunction triggered both by COVID-19 and a nosocomial bacterial infection, and eventually died. Although short-term prognosis could be considered benign in the majority of our patients, we should carefully monitor these individuals in order to detect early sign of clinical deterioration and graft dysfunction in the next few months.</AbstractText><CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morlacchi</LastName><ForeName>Letizia Corinna</ForeName><Initials>LC</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-4661-6471</Identifier><AffiliationInfo><Affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossetti</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gigli</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiovascular Disease Unit, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amati</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosso</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aliberti</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nosotti</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Respiratory Unit and Adult Cystic, Fibrosis Centre, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Transpl Infect Dis</MedlineTA><NlmUniqueID>100883688</NlmUniqueID><ISSNLinking>1398-2273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001784" MajorTopicYN="N">Blood Gas Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003550" MajorTopicYN="N">Cystic Fibrosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069340" MajorTopicYN="N">Deprescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054990" MajorTopicYN="N">Idiopathic Pulmonary Fibrosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016040" MajorTopicYN="Y">Lung Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011656" MajorTopicYN="N">Pulmonary Emphysema</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32510771</ArticleId><ArticleId IdType="doi">10.1111/tid.13356</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Saima A, Danziger-Izakov L, Luong ML, et al.Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic. https://community.ishlt.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=e48794c6-d4b3-cef4-2e53-dbcbb50b6a12&forceDialog=0</Citation></Reference><Reference><Citation>Kaltsas A, Sepkowitz K. Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. Curr Opin Infect Dis. 2012 Aug;25(4):423-430.</Citation></Reference><Reference><Citation>Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs. nonimmunocompromised hosts. Clin Infect Dis. 2014;58(2):214-224.</Citation></Reference><Reference><Citation>Aslam S, Mehra MR, COVID-19: yet another coronavirus challenge in transplantation. J Heart and Lung Transpl. 2020;39(5):408-409.</Citation></Reference><Reference><Citation>Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584-591.</Citation></Reference><Reference><Citation>Abadja F, Atemkeng S, Alamartine E, et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation. 2011 Aug 27;92(4):396-403.</Citation></Reference><Reference><Citation>Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or infection-beta1b improves outcome of MERS-CoV infection in a non human primate model of common marmoset. J Infect Dis. 2015;212(12):1904-1913.</Citation></Reference><Reference><Citation>Carbajo-Lozoya J, Müller MA, Kallies S, et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165(1):112-117.</Citation></Reference><Reference><Citation>Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancer. 2020;14:1022.</Citation></Reference><Reference><Citation>Romanelli A, Mascolo S. Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: a therapeutical analysis. Am J Transpl. 2020;3. https://doi.org/10.1111/ajt.15905</Citation></Reference><Reference><Citation>Marcus R, MohanSumit CJ, HusainSyed A, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. American Journal of Transplantation. 2020. https://doi.org/10.1111/ajt.15941</Citation></Reference><Reference><Citation>Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020;97(6):1083-1088.</Citation></Reference><Reference><Citation>Montagud-Marrahi E, Cofan F, Torregrosa JV, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single centre cohort of kidney recipients. Am J Transplant. 2020. http://doi.org/10.1111/ajt.15970</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.</Citation></Reference><Reference><Citation>Mousavi S, Moradi M, Khorshidahmad T, et al. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015;2015:1-14.</Citation></Reference><Reference><Citation>Thachil J. The Versatile Heparin in COVID-19. J Thromb Haemost. 2020;18(5):1020-1022.</Citation></Reference><Reference><Citation>Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with Severe Covid-19. N Engl J Med. 2020.382(19):1787-1799.</Citation></Reference><Reference><Citation>Wampler Muskardin TL IV anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of COVID19. ACR Open. Rheumatol. 2020. (in press).</Citation></Reference><Reference><Citation>Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther. 2020;14(2):73-76.</Citation></Reference><Reference><Citation>Peghin M, Los-Arcos I, Hirsch HH, et al. Community-acquired respiratory viruses are a risk factor for chronic lung allograft dysfunction. Clin Infect Dis. 2019;69(7):1192-1197.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32510771
|texte= COVID-19 in lung transplant recipients: A case series from Milan, Italy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32510771" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |